TORONTO, July 24, 2023 /PRNewswire/ – ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced today a multi-target license and option agreement with ImmunoGen, Inc….